NCT01787396View on ClinicalTrials.gov

Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d

PHASE3CompletedINTERVENTIONAL

Enrollment

433

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Gemigliptin 50mg

DRUG

Placebo(Metformin)

DRUG

Metformin

DRUG

Placebo(Gemigliptin)

Trial Locations (1)

110-062

LG Life Sciences, Seoul

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY

NCT01787396 - Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d | Biotech Hunter | Biotech Hunter